Skip to main content
. 2024 Aug 21;30(20):4755–4767. doi: 10.1158/1078-0432.CCR-24-0729

Figure 2.

Figure 2.

Pretreatment NKs and Tregs in patients with mRCC-REV. A, Upper: % NKs and % PD1+NKs in HD and REV groups. % NKs: HD (n = 39) vs. REV (n = 54), P = NS; % PD1+NKs: HD (n = 37) vs. REV (n = 51), P < 0.001. Lower: Representative comparison between HD#1457 and REV#4, HD#2 and REV#43. B, Upper: % CD107a+NKs in HD (n = 17) and REV (n = 56) groups, P < 0.05. Lower: Representative comparison between HD#5 and REV#34. C, Upper: % Tregs in HD (n = 34) and REV (n = 55) groups, P < 0.01. % PD1+Tregs: HD (n = 31) vs. REV (n = 51), P < 0.01. Lower: representative comparison between HD#2 and REV#35, HD#1362 and REV#26. D, Upper: % CFSE-Teff proliferation/Tregs dependent in HD (n = 15) vs. REV (n = 55) groups, P < 0.001. Lower: Representative comparison between HD#3 and REV#54. Box plot showing the data distribution across groups with minimum, median, and maximum values. Two-tailed test comparison of differences between two independent groups (*, P < 0.05; **, P < 0.01; ***, P < 0.001).